Purwet
Mixed Anxiety And Depressive Disorder
Explore 6 assets in Mixed Anxiety And Depressive Disorder →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
All Natural Medicine Clinic, LLC
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04846010CT.gov Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mixed Anxiety And Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Purwet (this asset) | All Natural Medicine Clinic, LLC | P1/2 | CC · 47 |
| Tenofovir Disoproxil Fumarate | Azienda Ospedaliera San Gerardo di Monza | P4 | B |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Massachusetts General Hospital | P4 | B |
| (±)-Ftc | Azienda Ospedaliera San Gerardo di Monza | P4 | B |
| Gardasil 9 Vaccine | Eunice Dube | P4 | B |
| Azithromycin | University of California, San Francisco | P4 | B |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | B |
| 17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL | Massachusetts General Hospital | P2 | CCC |
| Purapo | All Natural Medicine Clinic, LLC | P1/2 | CC |
+11 more in the Mixed Anxiety And Depressive Disorder cohort
Other indications for Purwet
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Post-Infectious Neuralgia | — | P1/2 | CCC · 48 |
| Reactive Arthritis | — | P1/2 | CCC · 48 |
| Post-Infectious Disorder | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Purwet in Mixed Anxiety And Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/purwet-mixed-anxiety-and-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →